T HE INSULIN -like growth factors (IGF-I and IGF-II) comprise a family of peptides that promote the proliferation and differentiation of a variety of cells (1, 2). Specific receptors for both growth factors have been described; the type I IGF receptor binds both IGF-I and IGF-II with a high affinity, whereas the type II receptor binds IGF-II with a high affinity and IGF-I with a low affinity (3). IGF-I has been shown to augment chemotaxis (4) and in vitro T-cell proliferation (4-7). These studies and the findings that human macrophages (8), rat leukocytes (9), and human T-cell blasts (Kooijman, R., unpublished observation) produce IGF-I indicate a possible role for IGF-I in immune function. Type I IGF receptors have been identified on human peripheral blood mononuclear cells (PBMC) (lo), but receptor studies on purified subpopulations thus far have only been performed for T-cells (4, 11) .
To obtain more insight into the potential role of IGF-I in the immune system, we investigated the expression of the type I IGF receptor in various subpopulations of human peripheral blood mononuclear cells. Using two-color flow cytometry, we found that natural killer (NK) cells, monocytes, B-cells, and both CD4+ and CD8+ T-cells possess type I IGF receptors. We were able to confirm the presence of type I IGF receptors on all subpopulations by radioligand binding assays on purified subpopulations. The specific bind-ing of ['251]IGF-I was inhibitable with aIR3. In addition, we show that the cytotoxic activity of NK cells can be enhanced by IGF-I.
Materials
and Methods 
Reagents

Cells
Peripheral blood was drawn from healthy adult donors by venepuncture, using 7.5 U/ml heparin as an anticoagulant. PBMC were purified from the heparinized blood by centrifugation on Ficoll/Isopaque (Pharmacia, Uppsala, Sweden) density gradients (1.077 g/ml) at 1000 x g for 20 min at room temperature.
For studies requiring large numbers of PBMC, these were purified from buffy coats (Red Cross Bloodbank, Utrecht, The Netherlands) with a citrate-phosphate-dextrose solution as an anticoagulant.
Blood was depleted of thrombocytes by gently shaking for 10 min in the presence of glass beads and 10 mM CaCl?, and PBMC were subsequently isolated as described above. Monocytes were isolated from PBMC by centrifugation on a Percoll (Pharmacia, Uppsala, Sweden) density gradient (1.063 g/ml) at 400 x g for 30 min at room temperature.
After NK cytotoxicity assay NK cell activity was assessed by means of a 3-h 51Cr release cytotoxicity assay, with the K562 cell line used as the target. Monocytes were removed from PBMC by carbonyl iron treatment -'-e remaining cells were incubated with or without IGF-I in round-b-nom microtiter wells (Nunc, Glostrup, Denmark) for 18 h at 37 C in 5% COZ. Culture medium consisted of RPM1 with 10% inactivated fetal calf serum (6, 17), 100 U/ ml penicillin, 100 pg/ml streptomycin, and 4 mM glutamine. Inactivation of fetal calf serum (FCS) was performed by treatment with dithiothreitol, a procedure that eliminates all detectable IGF-I and IGF-II (17). After incubation, the culture medium was replaced by RIM-5% FCS, 10 U/ ml interleukin-2 (Boerhinger, Mannheim, Germany), 100 U/ml penicillin, 100 Kg/ml streptomycin, 4 mM glutamine, and 0.5 PM 2-mercaptoethanol, After 2-h preincubation at 37 C in 5% CO?, the cells were added to 10,000 5'Cr-labeled target cells at various effecter/target cell ratios. Spontaneous and maximum release were determined by incubating labeled target cells in culture medium or 1% Triton X-100, respectively.
Cytotoxicity was expressed by the formula: % cytotoxicity = (experimental release -spontaneous release)/(total release -spontaneous release).
Whole blood (95 ~1) was incubated with 5 ~1 cuIR3 (100 pg/ml) for 30 min at 5 C. The mAb (~1R3 has been shown to bind specifically to type I IGF receptors (16). As controls, an isotype-matched mAb (IgGlK) of irrelevant specificity (keyhole limpet hemocyanin) was used. Subsequently, erythrocytes were lysed by the addition of 1 ml lysing solution (Becton Dickinson) and incubation for 10 min at room temperature. After one wash in PBS, the cells were incubated at 5 C with biotinylated goat antimouse Ig (4 rg/ml) in MEM containing 1% BSA, 0.02% NaN3, and 20% normal human serum. After 30 min, the cells were washed twice in MEM containing 1% BSA and 0.02% NaN3. 
IGF-I binding studies
Cells were washed twice in MEM containing 1% BSA. Binding studies were carried out with l-2 X lo6 cells in a final volume of 0.3 ml MEM-
Results
Immunofluorescence
The expression of type I IGF receptors on different subpopulations of PBMC was investigated using two-color flow cytometry. To avoid possible changes in receptor expression during the isolation of PBMC, the first labeling step with otIR3 was performed immediately after blood was taken. Type I receptors were detectable on all subpopulations, as depicted in a representative set of histograms (Fig. 1A ). Large differences in the mean expression of the type I receptors on cells from different donors were not found (Table 1) . Statistical analysis revealed that monocytes and CD4+ T-helper cells express significantly more receptors than CD%+ cytotoxic/suppressor T-cells and B-cells, and that B-cells express a lower number of receptors than all other cell types (P < 0.02). In all experiments, the T-cell subsets could be divided into two groups: one with a high fluorescence intensity, and the other with a low fluorescence intensity. The difference between the median fluorescence intensity of aIR3-labeled cells and the median intensity of control cells suggests a 5-to 20-fold difference in type I IGF receptor expression between the two groups of cells. It should be noted that differential expression of type I IGF receptors may influence otIR3 reactivity and, thus, affect the validity of receptor number estimation.
No differences in the amount of type I IGF receptors within other subsets were detected. (n = 5) T-Cells (CD3') 8.6 3~ 2.1 5.9 f 2.6 CD4+ T-cells 10.5 + 2.3 7.2 f 3.0 CD8' T-cells 7.5 f 1.4 5.1 f 2.4 Monocytes (CD14+) 10.2 + 0.9 6.3 + 4.3 B-Cells (CD20+) 4.9 + 1.4 3.4 + 1.1 NK cells (CDl6') 9.0 f 1.9 7.9 + 4.1
Several independent experiments using different donors were performed, as described in Fig. 1 . The specific binding of aIR3 is expressed in arbitrary fluorescence intensity units (SD) which are obtained by subtracting the mean fluorescence of the control cells from the mean fluorescence of aIR3-treated cells.
We also studied the expression of type I IGF receptors on isolated PBMC. Figure 1B and Table 1 show that every subpopulation of isolated PBMC binds otIR3, but to a lesser extent than the same cells that were labeled in whole blood. However, these differences were not significant. Scatchard plot analysis of the results from binding studies on purified monocytes revealed linear plots consistent with the presence of a single high affinity binding site (Fig. 2) . We found 734 f 426 binding sites/cell, with a Kd of 0.23 + 0.05 nM (n = 5). Table 2 shows that binding of ['251]IGF-I to this site can be inhibited by the addition of olIR3, indicating that the high affinity site is a type I IGF receptor. The specificity of IGF-I-binding sites on monocytes was also confirmed by competition binding assays. IGF-II and insulin competed with ['251 ]IGF-I for the binding sites with 4 and 833 times lower potencies than that of IGF-I, respectively (Fig. 3) . Scatchard analysis on these binding data revealed the same high affinity site as those observed using different concentrations of ['251]IGF-I (Fig. 3, inset) .
Scatchard plot analysis of purified (CD3+) T cells revealed both a high and a low affinity site in three donors (Fig. 4A ) and only one high affinity binding site in two donors (Fig.  4B) . When the amount of receptors was calculated using a two-site and a one-site model, respectively, we found a comparable number of high affinity binding sites. However, the mean Kd was higher for the two-binding site model (0.037 us. 0.064 nM, respectively; Table 2 ). The number of receptors on T-cells (230 + 52) should be considered as the average number on several distinct subsets (Fig. 1A) . As depicted in Table 2 The calculations for the low affinity site were inaccurate eases. To study the functional role of type I IGF receptors on NK cells, we investigated the effects of IGF-I on NK cell cytotoxicity. Cells were cultured for 18 h in RPM1 supplemented with inactivated FCS. Inactivated FCS has been shown previously to be suitable for measuring the effects of IGF-I on T-cell proliferation (6). Cell viability and the percentage of NK cells were assessed by trypan blue exclusion and flow cytometry using anti-CD16 (Leu llb), respectively. Neither parameter was affected by inactivation of FCS or addition of IGF-I to cells cultured in inactivated FCS (data not shown). As depicted in Fig. 5A , the cytotoxic activity of NK cells was reduced when the cells were cultured in inactivated FCS compared to cells cultured in nontreated FCS. The addition of 10-i' and lOmE M IGF-I partially restored the NK cell activity. The strongest effects on cytotoxicity were observed at lower effecter/target cell ratios. When NK cells from four different donors were tested at effecter/target cell ratios of 3:l and 6:1, we found positive effects of IGF-I, although one observation was not significant (Fig. 58) (data not shown). Binding of otIR3 to isolated PBMC was lower than that in whole blood. Since the reduction in binding was not the same in all subpopulations, it is unlikely that this effect is due to different conditions of incubation with the antibody. In addition, binding of cuIR3 sometimes decreased (up to 60%) during the purification of T-cells from PBMC, although the same labeling procedure was used before and after purification (data not shown). These results imply that the number of receptors estimated by Scatchard analysis on purified cells does not represent the number of receptors present in isolated PBMC or whole blood. We estimate that monocytes in whole blood possess about 500-2000 type I IGF receptors/cell, whereas the average number of receptors on T-cells is approximately 200-600.
Furthermore, our flow cytometric analysis shows that NK cells possess about the same number of receptors as monocytes and T-cells and that B-cells express about 45% less receptors.
Type I IGF receptors on T-cells have been shown to be functional in T-cell proliferation (4-7) and chemotaxis (4). In addition, the EDs0 of IGF-I for T-cell proliferation (0.12 nM) is proportional to the affinity of the type I receptor on these cells (6). The low EDso and the presence of high affinity type I IGF receptors open up the possibility that leukocyte-derived IGF-I, which has been shown to be produced in very low amounts by rat leukocytes (9), plays a role as an autocrine factor in the immune system. Our observation that resting CD4' and CDB+ T-cells express type I IGF receptors together with the binding data described by Johnson et al. (7) using purified CD4+ and CDB+ subsets of activated T-cells indicate that IGF-I might influence the actions of both T-helper cells (CD4+) and cytotoxic/suppressor T-cells (CDB+). This implies that there are potentially two mechanisms by which IGF-I can augment T-cell proliferation. Both modulation of Thelper cells, which secrete growth and differentiation factors, and modulation of T-suppressor cells can be involved. The presence of monocytes reduced the effects of IGF-I on T-cell proliferation (6) and NK cell cytotoxicity (data not shown). Whether these negative effects of monocytes are mediated by IGF-I remains to be elucidated. At the moment, the effects of IGF-I on the secretion of cytokines and prostaglandins that are known to affect T-cell and NK cell functions are being studied.
Our observation that IGF-I can modulate the cytotoxic activity of NK cells suggests that the type I IGF receptors are also functional on this cell type. There are indications that IGF-I might increase NK cell cytotoxicity in viva. In women with impaired endogenous GH secretion and in healthy adults that were treated with GH, the NK cell cytotoxicity correlated 'iyith the circulating levels of 20) . Furthermore, GH deficiency results in a lower level of IGF-I and is associated with an impairment in NK cell cytotoxicity in both experimental animals and humans (21-24). Long term treatment of GH-deficient children increased NK cell cytotoxicity (22). Further studies are required to assess whether there is a causal relation between IGF-I levels and NK cell function.
Since IGF-I secretion in different tissues can be regulated by several hormones (25), it would be interesting to address the role of IGF-I as a mediator of hormonal action on the immune system, such as the effects of GH on antibody production (26) and the effects of ACTH on antibody secretion, cytokine production, and NK cell function (27).
